drugset / Trial / NCT06733610
CAR T-cell Therapy Targeting CD19 and BCMA in Patients with AIHA Who Have Failed ≥3 Lines of Therapy.
Phase 1
Recruiting
15 enrolled
Institute of Hematology & Blood Diseases Hospital, China
Xi'niao Biotech · collab
NaSingle-groupOpen-labelTreatment
Summary
This is an investigator-initiated trial to evaluate the safety and efficacy of universal allogeneic anti-CD19/BCMA CAR T-cells in AIHA who have failed ≥ 3 lines of therapy.
Timeline
- Start
- 2024-12-05
- Primary completion
- 2026-02-05
- Completion
- 2026-12-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | UCAR T-cells | Cell therapy | — | Intravenous |